CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 10 2019
07 10 2019
Historique:
received:
29
01
2019
accepted:
14
08
2019
entrez:
9
10
2019
pubmed:
9
10
2019
medline:
30
10
2020
Statut:
epublish
Résumé
We sought to identify candidate biomarkers for early brain metastasis (BM) recurrence in patients who underwent craniotomy followed by adjuvant stereotactic radiosurgery. RNA sequencing was performed on eight resected brain metastasis tissue samples and revealed B-cell related genes to be highly expressed in patients who did not experience a distant brain failure and had prolonged overall survival. To translate the findings from RNA sequencing data, we performed immunohistochemistry to stain for B and T cell markers from formalin-fixed parffin-embedded tissue blocks on 13 patients. CD138 expressing plasma cells were identified and quantitatively assessed for each tumor sample. Patients' tumor tissues that expressed high levels of CD138 plasma cells (N = 4) had a statistically significant improvement in OS compared to low levels of CD138 (N = 9) (p = 0.01). Although these findings are preliminary, the significance of CD138 expressing plasma cells within BM specimens should be investigated in a larger cohort. Immunologic markers based on resection cavity analysis could be predictive for determining patient outcomes following cavity-directed SRS.
Identifiants
pubmed: 31591443
doi: 10.1038/s41598-019-50298-7
pii: 10.1038/s41598-019-50298-7
pmc: PMC6779906
doi:
Substances chimiques
Syndecan-1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14385Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Références
Neuro Oncol. 2014 Sep;16(9):1283-8
pubmed: 24558022
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
J Neurooncol. 2017 Nov;135(2):403-411
pubmed: 28828698
J Neurosurg. 2011 Jun;114(6):1585-91
pubmed: 21166567
Neurosurgery. 2014 Oct;75(4):409-17; discussion 417-8
pubmed: 24871143
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Neuro Oncol. 2017 Apr 1;19(4):558-566
pubmed: 27571883
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Clin Oncol. 2013 Jan 1;31(1):65-72
pubmed: 23213105
Cancer Lett. 2013 Jun 10;333(2):222-8
pubmed: 23370224
J Clin Oncol. 2013 Mar 10;31(8):1021-8
pubmed: 23401435
Oncotarget. 2015 Aug 7;6(22):18945-55
pubmed: 26087184
J Clin Oncol. 2000 Dec 1;18(23):3879-82
pubmed: 11099316
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e53-9
pubmed: 22342297
Cancer. 2014 Feb 1;120(3):433-41
pubmed: 24452675
J Immunol Methods. 2015 Jan;416:59-68
pubmed: 25445327
Immunity. 2015 Oct 20;43(4):631-3
pubmed: 26488814
Neurosurgery. 2007 Feb;60(2):277-83; discussion 283-4
pubmed: 17290178
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):131-141
pubmed: 28586952
Mol Cell Neurosci. 2013 Mar;53:42-51
pubmed: 23073146
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Transl Med. 2017 May 12;15(1):104
pubmed: 28499389
Neurosurgery. 2013 Oct;73(4):641-7; discussion 647
pubmed: 23842552
Cancer. 2015 Dec 1;121(23):4231-9
pubmed: 26372146
Cancer. 2015 Nov 1;121(21):3836-43
pubmed: 26242475
Int J Surg Oncol. 2012;2012:952345
pubmed: 22312545
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1008-1015
pubmed: 26050609
Proteomics. 2010 Mar;10(5):940-52
pubmed: 20049862
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):246-253
pubmed: 28068233